ARDELYX, INC. Increase (Decrease) in Other Accrued Liabilities
ARDELYX, INC. (ARDX) reported Increase (Decrease) in Other Accrued Liabilities of -$2.06 million for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccruedLiabilities · last filed 2018-08-07
- ARDELYX, INC. increase (decrease) in other accrued liabilities for the quarter ending 2018-06-30 was -$119.00K.
- ARDELYX, INC. increase (decrease) in other accrued liabilities for the quarter ending 2018-03-31 was -$1.95M, a 269.28% decline year-over-year.
- ARDELYX, INC. increase (decrease) in other accrued liabilities for the quarter ending 2017-09-30 was $341.00K, a 79.89% decline year-over-year.
- ARDELYX, INC. increase (decrease) in other accrued liabilities for the quarter ending 2017-06-30 was -$651.00K, a 145.43% decline year-over-year.
- ARDELYX, INC. increase (decrease) in other accrued liabilities for fiscal 2016 was $8.28M, a 314.10% increase from fiscal 2015.
- ARDELYX, INC. increase (decrease) in other accrued liabilities for fiscal 2015 was $2.00M, a 209.12% increase from fiscal 2014.
- ARDELYX, INC. increase (decrease) in other accrued liabilities for fiscal 2014 was $647.00K.
- ARDELYX, INC. increase (decrease) in other accrued liabilities for fiscal 2013 was -$1.01M, a 575.94% decline from fiscal 2012.
| Period end | Increase (Decrease) in Other Accrued Liabilities 3 month | Increase (Decrease) in Other Accrued Liabilities 6 month | Increase (Decrease) in Other Accrued Liabilities 6 month as first filed | Increase (Decrease) in Other Accrued Liabilities 9 month | Increase (Decrease) in Other Accrued Liabilities 9 month as first filed | Increase (Decrease) in Other Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2018-06-30 | -$119.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$2.06M 10-Q · filed 2018-08-07 | ||||
| 2018-03-31 | -$1.95M 10-Q · filed 2018-05-08 | |||||
| 2017-09-30 | $341.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$310.00K derived: sum of 2 quarters · filed 2018-08-07 | $839.00K 10-Q · filed 2017-11-07 | $2.34M derived: sum of 4 quarters · filed 2018-08-07 | ||
| 2017-06-30 | -$651.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $498.00K 10-Q · filed 2018-08-07 | $2.00M derived: sum of 3 quarters · filed 2018-08-07 | $3.69M derived: sum of 4 quarters · filed 2018-08-07 | ||
| 2017-03-31 | $1.15M 10-Q · filed 2018-05-08 | $2.65M derived: sum of 2 quarters · filed 2018-05-08 | $4.34M derived: sum of 3 quarters · filed 2018-05-08 | $5.78M derived: sum of 4 quarters · filed 2018-05-08 | ||
| 2016-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $3.19M derived: sum of 2 quarters · filed 2017-11-07 | $4.63M derived: sum of 3 quarters · filed 2017-11-07 | $8.28M 10-K · filed 2017-02-17 | ||
| 2016-09-30 | $1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $3.13M derived: sum of 2 quarters · filed 2017-11-07 | $6.79M 10-Q · filed 2017-11-07 | $1.16M derived: sum of 4 quarters · filed 2017-11-07 | ||
| 2016-06-30 | $1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $5.09M 10-Q · filed 2017-08-09 | -$535.00K derived: sum of 3 quarters · filed 2017-08-09 | $6.20M derived: sum of 4 quarters · filed 2017-08-09 | ||
| 2016-03-31 | $3.66M 10-Q · filed 2017-05-05 | -$1.97M derived: sum of 2 quarters · filed 2017-05-05 | $4.77M derived: sum of 3 quarters · filed 2017-05-05 | $5.79M derived: sum of 4 quarters · filed 2017-05-05 | ||
| 2015-12-31 | -$5.62M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $1.11M derived: sum of 2 quarters · filed 2017-02-17 | $2.13M derived: sum of 3 quarters · filed 2017-02-17 | $2.00M 10-K · filed 2017-02-17 | ||
| 2015-09-30 | $6.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $7.76M derived: sum of 2 quarters · filed 2016-11-07 | $7.62M 10-Q · filed 2016-11-07 | $7.58M derived: sum of 4 quarters · filed 2017-02-17 | ||
| 2015-06-30 | $1.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $886.00K 10-Q · filed 2016-08-08 | $844.00K derived: sum of 3 quarters · filed 2017-02-17 | $630.00K derived: sum of 4 quarters · filed 2017-02-17 | ||
| 2015-03-31 | -$134.00K 10-Q · filed 2016-05-09 | -$176.00K derived: sum of 2 quarters · filed 2017-02-17 | -$390.00K derived: sum of 3 quarters · filed 2017-02-17 | -$49.00K derived: sum of 4 quarters · filed 2017-02-17 | ||
| 2014-12-31 | -$42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | -$256.00K derived: sum of 2 quarters · filed 2017-02-17 | $85.00K derived: sum of 3 quarters · filed 2017-02-17 | $647.00K 10-K · filed 2017-02-17 | ||
| 2014-09-30 | -$214.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $127.00K derived: sum of 2 quarters · filed 2015-11-12 | $689.00K 10-Q · filed 2015-11-12 | $694.00K 10-Q · filed 2014-11-07 | $342.00K derived: sum of 4 quarters · filed 2016-03-04 | |
| 2014-06-30 | $341.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | $903.00K 10-Q · filed 2015-08-12 | $908.00K 10-Q · filed 2014-08-08 | $556.00K derived: sum of 3 quarters · filed 2016-03-04 | $466.00K derived: sum of 4 quarters · filed 2016-03-04 | |
| 2014-03-31 | $562.00K 10-Q · filed 2015-05-12 | $215.00K derived: sum of 2 quarters · filed 2016-03-04 | $125.00K derived: sum of 3 quarters · filed 2016-03-04 | |||
| 2013-12-31 | -$347.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-04 | -$437.00K derived: sum of 2 quarters · filed 2016-03-04 | -$1.01M 10-K · filed 2016-03-04 | |||
| 2013-09-30 | -$90.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$662.00K 10-Q · filed 2014-11-07 | ||||
| 2013-06-30 | -$572.00K 10-Q · filed 2014-08-08 | |||||
| 2012-12-31 | $212.00K 10-K · filed 2015-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |